View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 29, 2020

UK position in global clinical trials sector could receive boost after Covid-19

By Jamie Bell

The UK’s efforts to find vaccines and treatments for Covid-19 could elevate its status in the clinical trials sector, says an industry boss.

Cross-industry partnerships featuring UK-based pharma firms, government departments and hospitals are also “massively important” in tackling the crisis, said Tim Sheppard, general manager for Northern Europe at clinical research company IQVIA.

The University of Oxford is currently working with UK pharma giant AstraZeneca to test and develop a potential coronavirus vaccine, while the RECOVERY trial is one of the world’s largest clinical studies for Covid-19 treatments, testing drug therapies in multiple locations across the country.

Read the full article here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena